medRxiv preprint doi: https://doi.org/10.1101/2024.10.24.24316080; this version posted October 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	perpetuity.
It is made available under a	CC-BY-NC-ND 4.0 International license

1	Changing patterns of heart failure in China from 1990 to 2021: a secondary
2	analysis of the Global Burden of Disease study 2021
3	(Short title: Changing patterns of heart failure in China)
4	Qiwen Yang, MD ^{a,b,e} ; Rui Zhuang, MD, PhD ^{a,e} ; Diyang Lyu, MD, PhD ^a ; Donghua Xue, MD ^{a,b} ;
5	Chaofeng Niu, MD ^{a,b} ; Yujie Shi, MD, PhD ^{c,*} ; Meng Li, MD, PhD ^{a,d,*} ; Lijing Zhang, MD, PhD ^{a,*}
6 7	^a Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
8	^b Graduate School, Beijing University of Chinese Medicine, Beijing, China
9 10	^c Department of Cardiology, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, China
11	^d Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores
12	University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
13	^e These authors contributed equally to this work and share first authorship
14	* Correspondence:
15 16	Yujie Shi, <u>13910978461@163.com</u> , Department of Cardiology, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, China
17	Meng Li, <u>15201328277@163.com</u> , Department of Cardiology, Dongzhimen Hospital, Beijing
18	University of Chinese Medicine, Beijing, China; Liverpool Centre for Cardiovascular Science at
19	University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital,
20	Liverpool, United Kingdom.
21	Lijing Zhang, dzmyyccu@163.com, Department of Cardiology, Dongzhimen Hospital, Beijing
22	University of Chinese Medicine, Beijing, China.
23	

24 **The total word count:** 8607. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

Background: Heart failure is a leading public health issue in China, with a steadily increasing
burden. This study aims to assess the changing patterns of heart failure in China from 1990 to 2021,
providing evidence for informed healthcare strategies.

Methods: Data on prevalence, years lived with disability (YLDs), and their corresponding 95% uncertainty intervals (UI) were obtained from the Global Burden of Disease (GBD) Study 2021. The joinpoint regression model was used to identify both overall and localized trends of heart failure burden, and the age-period-cohort model served to analyze the contributions of age, period, and birth cohort separately. We further utilized the autoregressive integrated moving average (ARIMA) model to predict future trends of heart failure in the next 10 years.

35 **Results:** In 2021, 13099727 (95% UI, 11320895 to 15376467) individuals lived with heart failure 36 and this illness accounted for 1290810 (95% UI, 865894 to 1775731) YLDs in China. The burden of heart failure is more pronounced in males and the elderly, and ischemic heart disease has become the 37 leading cause since 2002. The age-standardized rates of prevalence and YLDs increased at average 38 39 annual percentage changes of 0.23% (95% CI, 0.20 to 0.26) and 0.25% (95% CI, 0.23 to 0.27) respectively. The curve of local drift showed a downward trend with age. Both the period and cohort 40 rate ratios have increased significantly over the last 30 years. By 2031, the age-standardized rates of 41 42 prevalence will decrease to 678.69 (95% CI, 640.75 to 716.63), while the age-standardized rates of 43 YLDs will increase to 69.19 (95% CI, 66.95 to 71.43).

44 Conclusions: The burden of heart failure in China remains concerning. The implementation of
45 comprehensive strategies should be taken into consideration, including strengthening primary
46 healthcare system, enhancing public awareness, and promoting cardiac rehabilitation.

47 Keywords: Heart failure, Global burden of disease, China, Prevalence, Years lived with disability

Non-standard Abbreviations and Acronyms			
AAPC	Average Annual Percentage Changes		
ACF	Autocorrelation Function		
AIC	Akaike Information Criterion		
APC	Annual Percentage Changes		

The APC model	The age-period-cohort model		
ARIMA	Autoregressive Integrated Moving Average		
ASR	Age-Standardized Rate		
DALYs	Disability-Adjusted Life-Years		
GBD	Global Burden of Disease		
HAQ	Healthcare Quality and Access		
HF	Heart Failure		
MR-BRT	Meta-Regression—Bayesian, Regularized, Trimmed		
UI	Uncertainty Interval		
WHO	World Health Organization		
YLDs	Years Lived with Disability		
YLLs	Years of Life Lost		

Clinical Perspective

What Is New?

This is the first study of the Global Burden of Disease (GBD) 2021 that comprehensively • analyzes the burden of heart failure in China over the past 30 years.

What Are the Clinical Implications?

- The burden of heart failure in China remains concerning. •
- Comprehensive strategies prioritizing primary healthcare system, public awareness, and • cardiac rehabilitation could be effective to mitigate the burden of heart failure.

Introduction 48

- Heart failure (HF) is a complex syndrome often identified by characteristic symptoms caused by 49
- structural or functional defects in ventricular filling or ejection of blood.^{1, 2} Approximately 55.5 50
- million people worldwide suffer from HF,³ which poses notable clinical and public health challenges, 51
- including impaired quality of life,^{2, 4} high rates of hospitalization,^{5, 6} poor prognosis,^{7, 8} and huge 52
- economic burden.^{9, 10} Therefore, strategies for the prevention and management are important to 53
- 54 minimize the burden of HF.
- 55 The Global Burden of Diseases, Injuries, and Risk Factors (GBD) study aims to quantify the

comparative magnitude of health loss, which provides an opportunity to understand in a given place, 56 time, and age-sex group what are the most important contributors to health loss.¹¹ Two recent 57 secondary analyses based on GBD 2019 illustrated the burden, trends, and regional variations in 58 global HF from different perspectives.^{12, 13} However, due to the scope defined by their primary 59 objectives, they were unable to provide detailed country- or region-specific analyses. In the past 30 60 years, China has made remarkable progress in the Healthcare Quality and Access (HAQ) Index, 61 ranking the first among middle-income countries.¹⁴ Still, China is struggling with steadily increasing 62 prevalence of HF and high mortality rate.^{15, 16} With China being the world's most populous country, it 63 contributes to nearly one-third of all HF cases globally, highlighting its substantial burden on both 64 national and international levels.¹³ As such, there is an urgent need to thoroughly analyze the GBD 65 data in China and implement targeted measures to reduce HF burden. Furthermore, recently released 66 67 GBD 2021 updated new etiologies and methodologies, which led to a significant variation in the data.^{3, 17} For example, regarding China's HF burden in 2019, GBD 2019 reported an age-standardized 68 prevalence of 1032.84 per 100000 population,¹² compared to 690.94 per 100000 population as 69 reported in GBD 2021 (https://vizhub.healthdata.org/gbd-results/). Considering such a large 70 71 discrepancy could skew the understanding of HF in China, it is crucial to use the most recent data. This first-to-date study provides a comprehensive analysis of HF data in China using GBD 2021. We 72 (1) quantified the burden and trends of HF over the past 30 years by sex, age, and cause; (2) assessed 73 localized trend changes; (3) disentangled the complex effects of age, period, and birth cohort on HF 74 75 burden; and (4) predicted the HF burden in the next decade. Our findings are expected to provide essential evidence for further healthcare strategies that can mitigate HF. 76

77 Methods

78 Data source

79 The GBD 2021 synthesized a vast array of data input sources and estimated the incidence,

80 prevalence, years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted

81 life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries across 204

82 countries and territories, as well as 811 subnational areas, covering the period from 1990 to 2021.³

83 All estimates for China and globally were obtained from the GBD Results Tool

84 (https://vizhub.healthdata.org/gbd-results/).

- A total of seven national or regional epidemiological studies were utilized as data sources for HF in
- 86 China in GBD 2021. Detailed information on these data sources and their characteristics is accessible
- through the GBD 2021 Sources Tool (<u>https://ghdx.healthdata.org/gbd-2021/sources</u>). The modelling
- 88 software MR-BRT (meta-regression—Bayesian, regularized, trimmed) was employed to adjust
- 89 systematic bias between definitions of HF. And overall prevalence of HF was estimated in
- 90 DisMod-MR 2.1 (Disease Modelling Meta-Regression, version 2.1) based on the input data. More
- 91 information on data processing and modeling methodologies can be found elsewhere.³
- 92 This study followed the Guidelines for Accurate and Transparent Health Estimation Reporting
- 93 (GATHER) to ensure the transparency and reliability of results, and the GATHER checklist is
- 94 presented in **Supplemental Table S1**.

95 **Definition and causal attribution**

HF, as a level 1 impairment in GBD 2021, is diagnosed using structured criteria, including the
Framingham or European Society of Cardiology (ESC) criteria.³ Briefly, the Framingham criteria
need to be satisfied with at least two major criteria or one major and two minor criteria,¹⁸ whereas
the ESC criteria require typical signs and symptoms caused by a structural and/or functional cardiac
abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or
during stress.¹⁹ HF is further divided into four subgroups based on clinical symptoms: treated, mild,
moderate and severe HF.³

HF can be attributed to 20 level 3 causes, as defined in a previous study,³ including: atrial fibrillation
and flutter; cardiomyopathy and myocarditis; chagas disease; chronic kidney disease (CKD); chronic
obstructive pulmonary disease (COPD); cirrhosis and other chronic liver diseases; congenital birth
defects; drug use disorders; endocarditis; endocrine, metabolic, blood, and immune disorders;
hemoglobinopathies and hemolytic anemias; hypertensive heart disease; interstitial lung disease and
pulmonary sarcoidosis; ischemic heart disease; non-rheumatic valvular heart disease; other

109 cardiovascular and circulatory diseases; pneumoconiosis; pulmonary arterial hypertension; rheumatic
110 heart disease; and stroke.

111 Statistical analysis

112 We used prevalence and YLDs to quantify the burden of HF in China during 1990-2021 by sex, age,

and cause. Age-standardized rates (ASRs) of prevalence and YLDs were also used to avoid the

114 influences of population size and age composition. YLDs were measured by taking the prevalence

multiplied by the disability weight for HF.³ 95% uncertainty interval (UI) was generated for all final

116 estimates as the 2.5th and 97.5th percentiles values of 500 draws.³

117 Joinpoint software (Version 5.2.0, <u>https://surveillance.cancer.gov/joinpoint/</u>) was utilized to further

assess trends in HF over the past 30 years. The joinpoint regression, a segmented linear model, is

designed to identify both overall and localized trends in data changes.²⁰ Annual percentage changes

120 (APC) reflect shifts in the slope within each time segment, while average annual percentage changes

121 (AAPC), calculated by weighting segment lengths, provide an overall trend for the entire period.

122 APC and AAPC are considered stable if their 95% confidence interval (CI) included 0. A *P*-value of

123 less than 0.05 indicates a significant increasing or decreasing trend.

124 The age-period-cohort (APC) model helps to assess the contribution of age, period, and cohort to the burden of HF separately, whereas traditional statistical methods are unable to reduce the collinearity 125 between these factors.²¹⁻²³ Age effect refers to the effect of changes in biologic aging. Period 126 effect represents the influence of human factors on HF burden that shared by all age groups 127 simultaneously, such as new equipment and medication. Cohort effect reflects changes in HF burden 128 129 among people of different birth years, which are influenced, for example, by exposure to risk factors. We employed 5 pivotal parameters for the analysis of APC model: net drift, local drift, longitudinal 130 age curve, period rate ratio, and cohort rate ratio. The net drift represents the overall estimated annual 131 132 percentage change in the ASRs, while the local drift reflects this change over time specific to a 133 certain age group. The longitudinal age curve is the fitted longitudinal age-specific rate in the 134 reference cohort adjusted for period effect. The period rate ratio measures the relative change in HF burden between two distinct time periods, and the cohort rate ratio compares HF burden across 135 136 groups born in different years. The calculation of these parameters has been detailed in previous

6

study.^{20, 22} To fit the APC model, age groups were defined as 0-4 (<5), 5-9, 10-14, ..., and 90-94. The
periods were similarly categorized into 5-year intervals (1992-1996, 1997-2001, ..., and 2017-2021).
Data for the period 1990 to 1991 and age groups >95 years were excluded from the analysis due to
their failure to span a 5-year interval.

The autoregressive integrated moving average (ARIMA) model has been introduced to account for 141 the complexity of time series data and is widely used to investigate time-dependent processes in 142 population health.²⁴ The basic structure of an ARIMA model is (p, d, q), where p is the order of the 143 autoregressive component, d is the degree of differencing (integration), and q is the order of the 144 moving average component.²⁵ To predict future trends of HF over the next 10 years, we applied 145 "auto.arima()" function, an automated algorithm from the "forecast" packages, which simplifies 146 model selection by identifying the best-fitting ARIMA model based on the Akaike Information 147 Criterion (AIC).²⁶ Subsequently, the normality and autocorrelation (white noise) of the residuals 148 from the fitted model were evaluated using the residual time series plot, autocorrelation function 149 (ACF) Plot, histogram with density plot, and the Ljung-Box test. A P-value greater than 0.05 in the 150 Ljung-Box test indicated no significant autocorrelation, supporting the model's adequacy.²⁵ 151

The joinpoint analysis was performed in joinpoint software (Version 5.2.0). Other analyses and
visualizations were conducted in R software (version 4.3.3), utilizing the "ggplot2", "nih.joinpoint",
"Epi", "forecast", and "forest" packages, among others.

155 **Ethics statement**

156 For GBD studies, the Institutional Review Board of the University of Washington reviewed and

157 approved a waiver of informed consent (<u>https://www.healthdata.org/research-analysis/gbd</u>).

158 **Results**

159 **Temporal trends in the burden of HF**

160 In 2021, there were 13099727 (95% UI, 11320895 to 15376467) HF cases in China, with ASRs of

161 692.50 (95% UI, 607.26 to 802.00) per 100000 population. This represents an increase from 1990,

162 when there were 4683303 (95% UI, 4036499 to 5435212) cases and ASRs of 644.58 (95% UI,

163 558.65 to 751.14) per 100000 population. Additionally, the number of YLDs more than doubled from 164 459512 (95% UI, 313552 to 630785) in 1990 to 1290810 (95% UI, 865894 to 1775731) in 2021, while the ASRs increased at AAPC of 0.25% (95% CI, 0.23 to 0.27) over the same period. Table 1 165 presents the prevalence and YLDs in 1990 and 2021, as well as the AAPC from 1990 to 2021, for 166 167 China and globally. Overall, the burden of HF has been on an upward trend over the last 30 years, with a more pronounced increase in China compared to the global level, as reflected by higher AAPC. 168 169 Since 1990, the number of HF cases in China has increased by 2.8 times, making up 23.6% of the 170 global total in 2021, compared to a 2.2-fold increase globally. However, from the perspective of ASRs of prevalence and YLDs, HF burden in China is higher than the global average. Trends in HF 171 burden for China and globally over the past 30 years are presented in Supplemental Figure S1. 172

Figure 1 illustrates the trends in sex-specific prevalence and YLDs in China, including both the 173 number and ASRs from 1990 to 2021. The prevalence of HF in both males and females has shown an 174 overall increasing trend, with males consistently experiencing a higher burden than females. Notably, 175 176 the gap between the cases of HF in males and females gradually widened after 1990 (2446913 vs 177 2236390), peaking in 2014 (5623587 vs 4598155), when the growth of the prevalence in males 178 slowed, leading to a gradual reduction in the gap, until 2020 (6577128 vs 6075682). The trends in 179 YLDs followed a similar pattern to those of prevalence. These localized trend changes are further 180 described in the results of joinpoint analysis.

181 **Figure 2** presents the age-specific burden of HF among males and females in China in 2021.

182 Generally, the number of HF cases for both males and females reaches its lowest point in the 20-24

age group (40317 and 31944), then increases with age, particularly rising sharply after the age of 65,

and peaking in the 70-74 age group (1372223 and 1121531). Notably, after the age of 80, the number

- 185 of cases in females surpasses that in males. Similar tendencies are observed in YLDs, where the
- 186 burden also increases with age and follows a comparable pattern across age groups.

187 Joinpoint analysis

184

188 The joinpoint analysis clearly quantifies the localized trend changes in ASRs of prevalence and

189 YLDs of HF (Figure 3). It is evident that the burden of HF has shown an upward trend over the past

190 30 years. After a significant decline in the ASRs of prevalence between 2000 and 2005 (APC =

191 -0.64%), a slow but nonsignificant decline was observed after 2014 (APC = -0.02%). Both males 192 (APC = -0.49%) and females (APC = -0.72%) experienced a significant decline in ASRs of prevalence between 2000 and 2005, while the ASRs of prevalence in males showed another 193 194 significant decline after 2014 (APC = -0.74%), narrowing the gap in the burden of HF between 195 males and females. Additionally, the ASRs of prevalence in males (AAPC = 0.24%) increased at a faster rate than in females (AAPC = 0.21%). The trend in ASRs of YLDs closely mirrors that of 196 197 prevalence. Meanwhile, it is noteworthy that the AAPC for the ASRs of YLDs in males, females, and 198 both sexes are higher than that of prevalence. Detailed results of the joinpoint analysis can be found 199 in Supplemental Table S2.

200 Age-period-cohort effects

201 The local drift and net drift of HF prevalence calculated using the APC model are shown in Figure 202 4A. The solid horizontal line and the dashed line represent the net drift (0.97%) with its 95%CI (0.76% to 1.19%), indicating that the overall ASRs of HF prevalence in China continues to increase. The 203 blue curve represents the local drift, which shows an inverted U-shape and intersects with the net 204 205 drift at one point. The growth rate for younger patients (\leq 50-54 age group) is higher than the overall level, indicating that the proportion of younger patients within the total HF population has gradually 206 increased from 1992 to 2021. In contrast, the proportion of elderly patients (≥55-59 age group) has 207 shown a downward trend. Additionally, the local drift for patients aged >70 is below 0, suggesting a 208 209 continuous decline in their prevalence from 1992 to 2021.

210 Figure 4B shows the longitudinal age curve of HF prevalence in China, independent of period effect. 211 The prevalence rate of HF remains stable up to the 60-64 age group, after which it increases rapidly with age. Figure 4C and Figure 4D present the period rate ratio and cohort rate ratio for the 212 213 prevalence of HF in China. From 1992 to 2021, the period rate ratio for HF showed continuous growth, with the growth rate slowing after the period 2012-2016. The cohort rate ratio for HF 214 showed a slight decline from the 1902 to 1937 birth cohorts, followed by a continuous increase in 215 216 more recent birth cohorts. The age-period-cohort effects on YLDs are very similar to those on 217 prevalence, and thus will not be elaborated here (Supplemental Figure S2).

9

218 Trends in causes of HF

Given that the majority of the HF burden is attributable to a few major causes, we selected the top 10 219 contributors in 2021 and plotted their trends from 1990 to 2021 (Figure 5). Focusing on these top 220 221 contributors allows us to gain clearer insights into the primary drivers of disease burden. It is evident 222 that the prevalence and YLDs of HF caused by ischemic heart disease and hypertensive heart disease far exceed those caused by other conditions. The contributions of ischemic heart disease, congenital 223 224 birth defects, and cardiomyopathy and myocarditis to the prevalence of HF have steadily increased, and their rankings have risen compared to 1990. Notably, the most significant increase was observed 225 in ischemic heart disease, which surpassed hypertensive heart disease after 2002 to become the 226 leading cause of HF. Although the prevalence of HF attributable to stroke is lower than that 227 attributable to COPD, the YLDs attributable to stroke surpassed those of COPD after 2000. 228

229 Furthermore, a Sankey diagram is used to depict the proportions of sex, cause, and age distribution

of HF in 2021, offering a clear overview of how these factors contribute to HF burden

231 (Supplemental Figure S3). Among all patients, the elderly (≥55 years) made up the largest

proportion. Ischemic heart disease and hypertensive heart disease were the leading causes of HF in

both the middle-aged (20-54 years) and elderly (\geq 55 years) patients, whereas congenital birth defects were the primary cause in younger patients (<20 years).

235 **Prediction of the HF burden in 2022–2031**

The ARIMA model is used to predict the trends in the prevalence and YLDs of HF over the next 10

years (Figure 6). The best-fitting model for the ASRs of prevalence is identified as (2, 1, 1), with an

AIC value of 93.15. The residual time series plot, ACF plot, histogram with density plot, and the

239 Ljung-Box test ($\chi^2 = 0.095$, P = 0.757) confirm the normality of residuals and lack of autocorrelation,

suggesting the model's adequacy (Supplemental Figure S4). Using the same approach, the ARIMA

model (2, 1, 0) for the ASRs of YLDs (AIC = -53.68) is developed. The adequacy of the model is

- validated by the aforementioned plots (**Supplemental Figure S5**) and the Ljung-Box test ($\chi^2 = 1.630$,
- 243 P = 0.202).
- Based on the fitted models, the ASRs of prevalence are projected to decrease from 688.28 (95% CI,

245 686.44 to 690.12) in 2022 to 673.05 (95% CI, 649.94 to 696.16) in 2026, followed by a slow

246 increase, reaching 678.69 (95% CI, 640.75 to 716.63) in 2031. In contrast, the ASRs of YLDs are

- 247 expected to continue increasing, from 67.83 (95% CI, 67.65 to 68.00) in 2022 to 69.19 (95% CI,
- 248 66.95 to 71.43) in 2031.

249 **Discussion**

250 To our knowledge, this is the first analysis of the GBD 2021 that comprehensively describes the burden of HF in China. Over the past 30 years, both the burden of HF and its growth rate in China 251 have exceeded the global levels. In 2021, approximately 13.1 million individuals lived with HF and 252 this illness accounted for 1.3 million YLDs in China. This is generally consistent with the prevalence 253 254 estimated using the China Hypertension Survey and the National Urban Employee Basic Medical Insurance Database.^{27, 28} Specifically, the burden is higher in males than in females, and it is the 255 heaviest among the elderly. As for the causes of HF, ischemic heart disease and hypertensive heart 256 257 disease stand out as the most striking causes among all patients, while congenital birth defects are the 258 leading cause among children and adolescents.

259 The algorithms and methodologies of the GBD study are continuously being optimized, making it essential to utilize the most up-to-date data.¹⁷ Our analysis of GBD 2021 reveals that both ASRs of 260 prevalence and YLDs in China and globally have increased in 2021 compared to 1990. This trend is 261 significantly different from what was presented in GBD 2019.¹² The joinpoint regression model 262 indicates that ASRs of prevalence and YLDs have ceased to increase after 2014, which may reflect 263 the positive outcomes of China's continuous improvements in HF management.^{29, 30} This stabilization 264 is largely attributed to the significant reduction in the burden of HF among males (Figure 3B, 3E). 265 Males generally bear a heavier burden than females in terms of risk factors and causes of HF,^{31, 32} 266 which aligns with the observed gender differences in the disease burden. Therefore, it is no surprise 267 that, under the same management, the improvement in HF burden is more pronounced in males. 268 Although ASRs of prevalence and YLDs have stabilized, HF remains a huge health care burden in 269 China due to population aging and the increasing absolute number of patients.^{28, 33} 270

271 The results of APC effects have further revealed the severe nature of the HF burden in China. The

longitudinal age curve shows a positive correlation between age and HF burden, consistent with
previous studies indicating that age is a risk factor for HF.^{34, 35} The prevalence and YLDs rates of HF
increase rapidly after the 60-64 age group, suggesting that greater efforts are needed to monitor and
prevent HF in individuals aged 65 and above.

The curve of local drift suggests that the proportion of younger patients among the HF population is gradually rising. In contrast, HF burden in individuals aged \geq 55-59 is growing at a rate slower than the overall average, even the burden among those aged \geq 70 is declining. Several factors may explain this trend. First, elderly patients are consistently a primary focus and may benefit more from the prevention and management efforts. Second, the unfavorable mortality rates³⁶ and survival rates³⁷ of HF may lead to the premature death of some patients, while those who survive tend to be relatively healthier.

Since the 2009 health-care reform, the Chinese government has doubled its expenditure in the health sector and established an integrated health-care delivery system based on primary health care.^{38, 39} However, according to the trend of the period effect, the risk of HF continues to increase, which is closely associated with changes in certain lifestyles and risk factors.

Diet, as one of the most important components of the Chinese lifestyles, has undergone significant 287 changes over the past few decades. People have shifted from a predominantly plant-based diet to a 288 Western-style diet characterized by high fat and high animal-based food intake.⁴⁰ The intake of 289 290 energy, carbohydrates, and protein has decreased, whereas fat consumption has significantly increased.⁴⁰ Furthermore, the consumption of whole grains, vegetables, and fruits in China over the 291 past 20 years has remained far below the levels recommended by national dietary guidelines, and 292 their inadequate intake constitutes a major dietary risk factor for ischemic heart disease and stroke.⁴¹ 293 294 Moreover, sodium intake in China has decreased since 1991, but it remains significantly higher than the World Health Organization (WHO) recommended level of <2.0 g/day, which is a major risk 295 factor for hypertension.⁴² The harmful effects of tobacco on cardiovascular and pulmonary health are 296 well-documented. As the largest tobacco-consuming country, China currently has over 300 million 297 298 smokers, with approximately half of them being tobacco dependent, making it more difficult for 299 them to initiate or succeed in quitting smoking.⁴³ Unfortunately, younger age and lower

socioeconomic status are associated with a higher risk of tobacco dependence.⁴³ Physical activity has
been proven to be associated with a lower risk of cardiovascular disease (CVD).⁴⁴ Over the past
decade, the prevalence and volume of physical activity among adults have increased slightly, but
they still remain at low levels. In contrast, the prevalence and volume of physical activity among
children and adolescents have shown a declining trend.^{45, 46}

Obesity, dyslipidemia, hypertension, and diabetes are fundamental cardiovascular risk factors, and 305 306 their worsening trends also explain the continuous increase in HF risk. Data from the China Chronic Disease and Risk Factors Surveillance program indicate that the standardized mean body mass index 307 (BMI) levels rose from 22.7 kg/m² to 24.4 kg/m², and the prevalence of obesity increased from 3.1% 308 to 8.1% over the past decade.⁴⁷ Another study comparing three national cross-sectional surveys 309 found that the prevalence of dyslipidemia among Chinese adults increased from 2002 to 2015, and 310 311 the weighted mean of low-density lipoprotein cholesterol (LDL-C) increased from 2.12 mmol/L to 2.87 mmol/L.⁴⁸ Multiple nationwide cross-sectional studies indicated that the prevalence of 312 hypertension increased from 5.1% in 1958 to 27.5% in 2018, with awareness and treatment rates 313 below 50%.¹⁵ Meanwhile, the prevalence of diabetes rose from 0.67% in 1980 to 11.2% in 2017.¹⁵ 314

To our relief, after the period 2012-2016, the growth of period rate ratio began to slow. This 315 improvement can be attributed not only to sustained financial support but also to significant progress 316 in the quality of HF management in China, including standardized diagnosis, guideline-directed 317 medical therapies, and device therapies.⁴⁹ The trend of the period effect is likely to improve further 318 with a deeper understanding of HF and the establishment of the four pillars of HF therapy after 319 2021.^{50, 51} While the period effect has a broad impact across all age groups, the cohort effect 320 321 highlights that younger generations are at higher risk of HF. Individuals from more recent birth 322 cohorts are exposed to Westernized diets and other unhealthy lifestyles at a younger age, and they are also more vulnerable to risk factors of HF during their growth. In this context, it is essential to 323 strengthen health education and regular screening for children and adolescents to mitigate the risk of 324 325 early onset HF.

In line with global trends,¹³ hypertensive heart disease and ischemic heart disease are the leading causes of HF in China. To address these major causes, we believe it is crucial to enhance public

health education to improve awareness and treatment rates, while general practitioners need to 328 329 identify and manage related risk factors as early as possible. This presents a challenge to China's primary health care system. For children and adolescents, congenital heart disease ranks first among 330 congenital birth defects, which is the main cause of HF.¹⁵ A meta-analysis has filled the gap left by 331 the GBD study, showing that atrial septal defect, patent ductus arteriosus, and ventricular septal 332 defect are the most common subtypes of congenital heart disease in China, accounting for 27.37%, 333 20.66%, and 18.72%, respectively.⁵² Since the establishment of a screening and diagnosis system for 334 congenital heart disease by the Chinese government in 2002, prenatal screening coverage and 335 detection rates have continuously improved, which partly explain the slight increase in congenital 336 birth defects after 2000.⁵³ However, China still faces issues regarding insufficient screening, 337 diagnosis, and treatment capabilities in central and western regions, as well as rural areas.⁵³ Besides, 338 339 the burden of HF attributable to COPD has declined significantly after 2000, largely due to the strengthened anti-smoking policies.^{54, 55} It is noteworthy that ASRs of prevalence attributable to 340 341 stroke rank fifth, whereas ASRs of YLDs rank third, indicating that HF caused by stroke has a pronounced impact on patients' quality of life. Considering that stroke and HF share several major 342 risk factors,⁵⁶ clinicians must pay close attention to the cardiac function of stroke patients when 343 initiating therapies. Early identification and intervention for HF are important to reduce the impact 344 345 on the quality of life.

The course of HF is prolonged, and symptoms often lag behind the progression of the disease itself. 346 347 The ARIMA model predicts that ASRs of prevalence will first decrease and then slightly increase over the next decade. This trend may be the result of continuous improvements in HF management, 348 sustained financial support, and the high mortality rates among elderly patients. On the other hand, 349 350 the continuous increase in ASRs of YLDs suggests that the quality of life of HF patients will further 351 deteriorate. This is associated with worsening HF risk factors and its earlier onset tendency, as the 352 increasing proportion of younger patients indicates that more individuals will be affected by HF for longer durations. The results of ARIMA model indicate that improving patients' quality of life will be 353 354 a prominent challenge in the future. We believe that, in addition to pharmacological treatments, 355 cardiac rehabilitation is a promising solution. Cardiac rehabilitation is a comprehensive intervention 356 that includes, but is not limited to, exercise training, nutritional advice, patient education, risk factor

14

control, and psychological support.⁵⁷ High quality studies have shown that cardiac rehabilitation can 357 effectively reduce the risk of hospitalization in HF patients, while also lowering healthcare costs and 358 improving quality of life.⁵⁸ Cardiac rehabilitation is even considered the fifth pillar in the 359 management of HF.⁵⁹ However, the importance attached to cardiac rehabilitation in China is far from 360 sufficient. A cross-sectional survey of 124 large medical centers in China showed that only 30 of 361 them provided cardiac rehabilitation services, and the estimated availability of cardiac rehabilitation 362 programs was about 2 programs per 100 million inhabitants, which is much lower compared to the 363 availability in the United States.^{60, 61} We recommend increasing awareness of the benefits of cardiac 364 rehabilitation among both patients and medical staff, and actively promoting cardiac rehabilitation 365 programs in hospitals. This is of great value in improving the quality of life and mitigating the 366 growth of YLDs. 367

368 We conducted a comprehensive analysis of the changing patterns of HF in China using the latest GBD 2021 data, but several limitations should be considered when interpreting the results. First, we 369 were unable to report the burden of specific HF subtypes (HF with reduced/mildly reduced/preserved 370 ejection fraction, HFrEF/HFmrEF/HFpEF). Since each type differs in epidemiology, 371 pathophysiology, treatment, and prognosis,^{27, 62-65} this prevents us from providing more tailored 372 advice on healthcare strategies. Second, there are disparities in economic development and 373 374 healthcare quality across provinces in China, yet we were unable to obtain provincial-level data to describe the geographical distribution of HF burden. Third, in the GBD study, HF is categorized as 375 376 an "impairment", which limits its burden assessment to prevalence and YLDs. The lack of data on HF mortality and YLLs may hinders the accurate description of its threat to public health, which 377 further impacts the allocation of healthcare resources and policymaking. Interestingly, CKD, which 378 is also an end-stage disease with a similar five-year survival rate to HF,^{37,66} is categorized as a "cause 379 380 of death or injury". The classification of HF in the GBD study may need reconsideration in the future. 381 Lastly, the ARIMA model is a time series model which integrates the comprehensive effects of influencing factors into the time variable, characterized by simplicity and efficiency.⁶⁷ However, 382 relying solely on the time variable makes it difficult to predict the long-term trend of HF burden. 383 384 Particularly, when new influencing factors emerge in the future, such as advances in treatment or 385 policy changes, the predictive power may decline. Therefore, our predictions should be interpreted

386 with caution.

387 Conclusions

Although the ASRs of prevalence and YLDs of HF in China gradually stabilized from 1990 to 2021, 388 389 the burden remains substantial. The HF burden is heavier in males and the elderly, with ischemic heart disease and hypertensive heart disease as the primary causes, while congenital birth defects are 390 391 the leading causes among children and adolescents. Lifestyle shifts and the worsening burden of cardiovascular risk factors continue to drive the risk of HF, and younger generations tend to be more 392 vulnerable to HF. Given the severity of the HF burden in China, comprehensive strategies must be 393 considered: (1) strengthening the primary healthcare system to improve prevention and early 394 395 treatment of the major causes (ischemic heart disease, hypertensive heart disease, and congenital 396 birth defects) and common risk factors (obesity, dyslipidemia, hypertension, and diabetes) of HF; (2) enhancing public awareness to encourage healthy lifestyle (balanced diet, reduced salt intake, 397 398 smoking cessation, and increased physical activity), as well as improving awareness and treatment 399 rates for the disease; (3) promoting cardiac rehabilitation to enhance quality of life and mitigate the 400 growth of YLDs.

401 Acknowledgments

The authors thank the GBD 2021 Diseases and Injuries Collaborators and the Institute for Health
Metrics and Evaluation (IHME) for sharing the high-quality data.

404 Source of Funding

This study was supported by the National Key Research and Development Program of China (grant
number: 2022YFC3500101).

407 **Disclosures**

408 None.

16

409 **Data sharing statement**

410 Datasets analyzed for this study are publicly available at https://vizhub.healthdata.org/gbd-results/.

411 Supplemental Material

- 412 Tables S1-S2
- 413 Figure S1-S5

414 **References**

415 1. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. *The Lancet*.
416 2019;393:1034-1044.

417 2. Authors TFM, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J,
418 Čelutkienė J, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *EUR J*419 *HEART FAIL*. 2022;24:4-131.

3. Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, Abd ElHafeez S, Abdelmasseh M,
Abd-Elsalam S, Abdollahi A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted
life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories
and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*. 2024;403:2133-2161.

425 4. Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data 426 acquired in the baseline phase of the CARE-HF study. *EUR J HEART FAIL*. 2005;7:243-251.

427 5. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *NAT REV CARDIOL*. 2016;13:368-378.

Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, Mamas MA, Khunti K, Kadam UT. 20-year trends
in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. *The Lancet Public Health*. 2019;4:e406-e420.

431 7. Janaswamy P, Walters TE, Nazer B, Lee RJ. Current Treatment Strategies for Heart Failure: Role of Device
432 Therapy and LV Reconstruction. *Current Treatment Options in Cardiovascular Medicine*. 2016;18:57.

4338. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal434Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction.

435 JACC: Heart Failure. 2018;6:678-685.

436 9. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *INT J*437 *CARDIOL*. 2014;171:368-376.

438 10. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR,

439 Cheng S, Delling FN, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart 440 Association. *CIRCULATION*. 2020;141:e139-e596.

441 11. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, Naghavi M, Salomon JA, Shibuya K, Vos T, et

al. GBD 2010: design, definitions, and metrics. *The Lancet*. 2012;380:2063-2066.

443 12. Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, Weng F, Zhu S, Xiang B, Zhou X, et al. Burden, Trends, and

- 444 Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 445 Study. JAM HEART ASSOC. 2023;12:e027852.
- 446 13. Liu Z, Li Z, Li X, Yan Y, Liu J, Wang J, Guan J, Xin A, Zhang F, Ouyang W, et al. Global trends in heart failure
- 447 from 1990 to 2019: An age-period-cohort analysis from the Global Burden of Disease study. ESC HEART FAIL.

448 2024; Published online June 27, 2024.

- 449 14. Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E, Abajobir AA, Abate KH, Abbafati C, Abbas
- 450 KM, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195
- 451 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet. 452 2017;390:231-266.
- 453 15. The Writing Committee Of The Report On Cardiovascular Health And Diseases In China. Report on Cardiovascular 454 Health and Diseases in China 2022: an Updated Summary. BIOMED ENVIRON SCI. 2023;36:669-701.
- 455 16. Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao Y, et al. Contemporary Epidemiology,
- 456 Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure 457 (China-HF) Registry. J CARD FAIL. 2017;23:868-875.
- 458 17. Institute For Health Metrics And Evaluation IHME. GBD 2021 Cause and Risk Summary: Heart failure. Seattle,
- 459 USA: IHME, University of Washington, 2024. 2024;2024.
- 460 18. McKee PA, Castelli WP, McNamara PM, Kannel WB. The Natural History of Congestive Heart Failure: The 461 Framingham Study. NEW ENGL J MED. 1971;285:1441-1446.
- 462 19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V,
- 463 Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task
- 464 Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology 465 (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. EUR HEART J. 466 2016;37:2129-2200.
- 467 20. Kim H, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer 468 rates. STAT MED. 2000;19:335-351.
- 469 21. Rosenberg PS, Anderson WF. Age-Period-Cohort Models in Cancer Surveillance Research: Ready for Prime Time? 470 Cancer Epidemiology, Biomarkers & Prevention. 2011;20:1263-1268.
- 471 22. Rosenberg PS. A new age-period-cohort model for cancer surveillance research. STAT METHODS MED RES. 472 2018;28:3363-3391.
- 473 23. Bell A. Age period cohort analysis: a review of what we should and shouldn't do. ANN HUM BIOL. 474 2020;47:208-217.
- 475 24. Wagner B, Cleland K. Using autoregressive integrated moving average models for time series analysis of 476 observational data. BMJ-BRIT MED J. 2023;383:p2739.
- 477 25. Schaffer AL, Dobbins TA, Pearson S. Interrupted time series analysis using autoregressive integrated moving
- 478 average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC MED RES METHODOL. 479 2021;21:58.
- 480 26. Hyndman RJ, Khandakar Y. Automatic Time Series Forecasting: The forecast Package for R. J STAT SOFTW. 481 2008;27:1-22.
- 482 27. Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, Zheng C, Kang Y, Jiang L, Zhu Z, et al. Prevalence of heart
- 483 failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015. EUR J HEART FAIL.
- 484 2019;21:1329-1337.
- 485 28. Wang H, Chai K, Du M, Wang S, Cai J, Li Y, Zeng P, Zhu W, Zhan S, Yang J. Prevalence and Incidence of Heart
- 486 Failure Among Urban Patients in China: A National Population-Based Analysis. Circulation: Heart Failure.

487 2021;14:e008406.

- 488 29. Chinese Society Of Cardiology Of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology.
- 489 Chinese guidelines for the diagnosis and treatment of heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi. 490 2014;42:98-122.
- 491 30. Heart Failure Group Of Chinese Society Of Cardiology Of Chinese Medical Association, Chinese Heart Failure 492 Association Of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese 493 guidelines for the diagnosis and treatment of heart failure 2018. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46:760-789.
- 494 31. Walli-Attaei M, Rosengren A, Rangarajan S, Breet Y, Abdul-Razak S, Sharief WA, Alhabib KF, Avezum A,
- 495 Chifamba J, Diaz R, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women
- 496 compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. The 497 Lancet. 2022;400:811-821.
- 498 32. Li Y, Lu Y, Hurwitz EL, Wu Y. Gender Disparities of Heart Disease and the Association with Smoking and
- 499 Drinking Behavior among Middle-Aged and Older Adults, a Cross-Sectional Study of Data from the US Health and
- 500 Retirement Study and the China Health and Retirement Longitudinal Study. International Journal of Environmental
- 501 Research and Public Health. 2022;19.
- 502 33. Luo Y, Su B, Zheng X. Trends and Challenges for Population and Health During Population Aging — China, 503 2015-2050. CHINA CDC WEEKLY. 2021;3:593-598.
- 504 34. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J AM COLL 505 CARDIOL. 1993;22:A6-A13.
- 506 35. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JCM, Stricker
- 507 BHC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The 508 Rotterdam Study. EUR HEART J. 2004;25:1614-1619.
- 509 36. HU S. Heart failure in China: epidemiology and current management. J GERIATR CARDIOL. 2024;21:631-641.
- 510 37. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the 511 community: a systematic review and meta-analysis. EUR J HEART FAIL. 2019;21:1306-1325.
- 512 38. Li H, Liu K, Gu J, Zhang Y, Qiao Y, Sun X. The development and impact of primary health care in China from
- 513 1949 to 2015: A focused review. The International Journal of Health Planning and Management. 2017;32:339-350.
- 514 39. Yip W, Fu H, Chen AT, Zhai T, Jian W, Xu R, Pan J, Hu M, Zhou Z, Chen Q, et al. 10 years of health-care reform 515 in China: progress and gaps in Universal Health Coverage. The Lancet. 2019;394:1192-1204.
- 40. Bu T, Tang D, Liu Y, Chen D. Trends in Dietary Patterns and Diet-related Behaviors in China. AM J HEALTH 516 517 BEHAV. 2021;45:371-383.
- 518 41. Fang Y, Xia J, Lian Y, Zhang M, Kang Y, Zhao Z, Wang L, Yin P, Wang Z, Ye C, et al. The burden of 519 cardiovascular disease attributable to dietary risk factors in the provinces of China, 2002–2018: a nationwide 520 population-based study. The Lancet Regional Health - Western Pacific. 2023;37.
- 521 42. Du S, Wang H, Zhang B, Popkin BM. Dietary Potassium Intake Remains Low and Sodium Intake Remains High,
- 522 and Most Sodium is Derived from Home Food Preparation for Chinese Adults, 1991-2015 Trends. The Journal of 523 Nutrition. 2020;150:1230-1239.
- 524 43. Liu Z, Li Y, Cui Z, Li L, Nie X, Yu C, Shan G, Zhou X, Qin R, Cheng A, et al. Prevalence of tobacco dependence 525 and associated factors in China: Findings from nationwide China Health Literacy Survey during 2018-19. The Lancet 526 Regional Health – Western Pacific. 2022;24:100464.
- 527 44. Eijsvogels TMH, Molossi S, Lee D, Emery MS, Thompson PD. Exercise at the Extremes: The Amount of Exercise
- 528 to Reduce Cardiovascular Events. JAM COLL CARDIOL. 2016;67:316-329.
- 529 45. Zou Q, Wang H, Du W, Su C, Ouyang Y, Wang Z, Ding G, Zhang B. Trends in Leisure-Time Physical Activity

530 Among Chinese Adults - China, 2000-2015. CHINA CDC WEEKLY. 2020;2:135-139.

- 531 46. Yang X, Leung AW, Jago R, Yu SC, Zhao WH. Physical Activity and Sedentary Behaviors among Chinese 532 Children: Recent Trends and Correlates. BIOMED ENVIRON SCI. 2021;34:425-438.
- 533 47. Wang L, Zhou B, Zhao Z, Yang L, Zhang M, Jiang Y, Li Y, Zhou M, Wang L, Huang Z, et al. Body-mass index 534 and obesity in urban and rural China: findings from consecutive nationally representative surveys during 535 2004–18. The Lancet. 2021;398:53-63.
- 536 48. Song PK, Man QQ, Li H, Pang SJ, Jia SS, Li YQ, He L, Zhao WH, Zhang J. Trends in Lipids Level and
- 537 Dyslipidemia among Chinese Adults, 2002-2015. BIOMED ENVIRON SCI. 2019;32:559-570.
- 538 49. Zhang Y, Gao C, Greene SJ, Greenberg BH, Butler J, Yu J, Zheng Z, Ma G, Wang L, Yang P, et al. Clinical 539 performance and quality measures for heart failure management in China: the China-Heart Failure registry study. ESC 540 HEART FAIL. 2023;10:342-352.
- 541 50. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler
- 542 J, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart
- 543 Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the
- 544 Universal Definition of Heart Failure. J CARD FAIL. 2021;27:387-413.
- 545 51. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel
- 546 O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task
- 547 Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) 548 With the special contribution of the Heart Failure Association (HFA) of the ESC. EUR HEART J. 2021;42:3599-3726.
- 549 52. Zhao L, Chen L, Yang T, Wang T, Zhang S, Chen L, Ye Z, Luo L, Qin J. Birth prevalence of congenital heart 550 disease in China, 1980-2019: a systematic review and meta-analysis of 617 studies. EUR J EPIDEMIOL. 551 2020;35:631-642.
- 552 53. Zhang Y, Wang J, Zhao J, Huang G, Liu K, Pan W, Sun L, Li J, Xu W, He C, et al. Current status and challenges in 553 prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China. The Lancet Child & 554 Adolescent Health. 2023;7:479-489.
- 555 54. Lv J, Su M, Hong Z, Zhang T, Huang X, Wang B, Li L. Implementation of the WHO Framework Convention on 556 Tobacco Control in mainland China. TOB CONTROL. 2011;20:309.
- 557 55. Guo B, Gan H, Xue M, Huang Z, Lin Z, Li S, Zheng P, Sun B. The Changing and Predicted Trends in Chronic 558 Obstructive Pulmonary Disease Burden in China, the United States, and India from 1990 to 2030. INT J CHRONIC 559 OBSTR. 2024;19:695-706.
- 560 56. Feigin VL, Abate MD, Abate YH, Abd ElHafeez S, Abd-Allah F, Abdelalim A, Abdelkader A, Abdelmasseh M,
- 561 Abd-Elsalam S, Abdi P, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic 562 analysis for the Global Burden of Disease Study 2021. The Lancet Neurology. 2024;23:973-1003.
- 563 57. Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, Lin G, Lindenfeld J, O Connor C,
- 564 Panjrath G, et al. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel. J AM COLL CARDIOL.
- 565 2021;77:1454-1469.
- 566 58. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats A, Dalal H, Rees K, Singh SJ, Taylor RS. Exercise-567 based cardiac rehabilitation for adults with heart failure. COCHRANE DB SYST REV. 2019.
- 568 59. Taylor RS, Dalal HM, Zwisler A. Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of 569 care? EUR HEART J. 2023;44:1511-1518.
- 570 60. Zhang Z, Pack Q, Squires RW, Lopez-Jimenez F, Yu L, Thomas RJ. Availability and characteristics of cardiac
- 571 rehabilitation programmes in China. Heart Asia. 2016;8:9.
- 572 61. Turk-Adawi K, Sarrafzadegan N, Grace SL. Global availability of cardiac rehabilitation. NAT REV CARDIOL.

573 2014;11:586-596.

- 574 62. Borlaug BA, Redfield MM. Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure 575
- Spectrum. CIRCULATION. 2011;123:2006-2014.
- 576 63. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. 577 EUR HEART J. 2011;32:670-679.
- 578 64. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-Specific
- 579 Treatment of Heart Failure With Preserved Ejection Fraction. CIRCULATION. 2016;134:73-90.
- 580 65. Beghini A, Sammartino AM, Papp Z, von Haehling S, Biegus J, Ponikowski P, Adamo M, Falco L, Lombardi CM,
- 581 Pagnesi M, et al. 2024 update in heart failure. ESC HEART FAIL. 2024.
- 66. Wu B, Wei CH, Yang C, Lin M, Hsu C, Hsu Y, Lin S, Tarng D. Mortality rate of end-stage kidney disease patients 582 583 in Taiwan. J FORMOS MED ASSOC. 2022;121:S12-S19.
- 584 67. Lou H, Wang X, Gao Y, Zeng Q. Comparison of ARIMA model, DNN model and LSTM model in predicting
- 585 disease burden of occupational pneumoconiosis in Tianjin, China. BMC PUBLIC HEALTH. 2022;22:2167.

586

587

	s Metrics	1990		2021		1990-2021
Regions		Number (95% UI)	ASRs per	Number (95% UI)	ASRs per	AAPC in
			100K		100K	ASRs (95%
			(95% UI)		(95% UI)	CI)
China	Prevalence	4683303	644.58	13099727	692.50	0.23 (0.20 to
		(4036499 to	(558.65 to	(11320895 to	(607.26 to	0.26)
		5435212)	751.14)	15376467)	802.00)	
	YLDs	459512	62.83	1290810	67.79	0.25 (0.23 to
		(313552 to	(42.81 to	(865894 to	(45.92 to	0.27)
		630785)	87.18)	1775731)	93.34)	
Global	Prevalence	25433220	641.14	55496833	676.68	0.17 (0.14 to
		(22319175 to	(556.29 to	(48996498 to	(598.68 to	0.20)
		29214320)	745.46)	63842413)	776.84)	
	YLDs	2429267	61.07	5311084	64.70	0.18 (0.15 to
		(1644896 to	(41.34 to	(3626094 to	(44.20 to	0.21)
		3347611)	85.01)	7360663)	89.47)	

588 **Table 1** The burden of heart failure in China and globally

589 UI, uncertainty interval; ASR, age-standardized rate; AAPC, average annual percentage change; CI,
590 confidence interval; YLDs, years lived with disability.

591

592

Figure 1 Trends in the burden of heart failure in China by sex from 1990 to 2021. (A) Number of
prevalent cases and ASRs. (B) Number of YLDs and ASRs. The translucent ribbons and black error
bars represent the 95% UI. ASR, age-standardized rate; YLDs, years lived with disability.

596

597

598 **Figure 2** Age-specific burden of heart failure in China, 2021. (A) Number of prevalent cases by age.

599 (B) Number of YLDs by age. YLDs, years lived with disability.

600

601

Figure 3 Joinpoint analysis of the burden of heart failure in China from 1990 to 2021. (A-C) Trends in age-standardized prevalence for both sexes, males, and females, respectively. (D-F) Trends in age-standardized YLDs for both sexes, males, and females, respectively. Significant trends are indicated with an asterisk (*) based on *P*-values of APC and AAPC. ASR, age-standardized rate; APC, annual percentage changes; AAPC, average annual percentage change; YLDs, years lived with disability.

608

609

Figure 4 Age-period-cohort effects on the prevalence of heart failure in China from 1992 to 2021. (A) 610 611 Net drift and local drift for the prevalence of heart failure. The dashed lines and translucent ribbons represent the 95% CI of the net drift and the 95% CI of the local drift, respectively. (B) Longitudinal 612 age curves for the prevalence of heart failure, adjusted for period effect. The translucent ribbons 613 indicate the 95% CI of the age-specific prevalence rate. (C) Period rate ratio of the prevalence of 614 615 heart failure, adjusted for age and cohort effects. The translucent ribbons indicate the 95% CI of the period rate ratio, and the period 2002 to 2006 is the reference period. (D) Cohort rate ratio of the 616 prevalence of heart failure, adjusted for age and period effects. The translucent ribbons indicate the 617 95% CI of the cohort rate ratio, and cohort 1957 is the reference cohort. 618

619

620


Figure 5 Trends in age-standardized rates of prevalence (A) and YLDs (B) attributable to major
causes of heart failure in China from 1990 to 2021. ASR, age-standardized rate; YLDs, years lived
with disability.


624

625


Figure 6 Predicted trends in age-standardized rates of heart failure prevalence (A) and YLDs (B) in
China from 2022 to 2031. The black lines represent the trend over the past 30 years, while the blue
lines with black dots represent the forecast for the next 10 years. ARIMA, the autoregressive

629 integrated moving average; ASR, age-standardized rate; YLDs, years lived with disability.






В




Female


Male



Ε


В






F

С



Α





- Observed-Female
- 1990–1997 APC: 0.39*


- ----- 2005-2015 APC: 0.29*
- 2015–2019 APC: 1.09*
- 2019–2021 APC: 0.07
 - AAPC: 0.21*

- Observed-Female
- 1990–1997 APC: 0.46*
- 2000–2005 APC: –0.66*
- ----- 2005-2015 APC: 0.23*
- ---- 2015-2019 APC: 1.05*
- 2019–2021 APC: 0.12


AAPC: 0.23*







- --- Atrial fibrillation and flutter
- Cardiomyopathy and myocarditis
- --- Chronic kidney disease
- Chronic obstructive pulmonary disease
- --- Congenital birth defects
- Hypertensive heart disease
- --- Ischemic heart disease
- Non–rheumatic valvular heart disease
- --- Rheumatic heart disease
- Stroke



Forecasts from ARIMA(2,1,0)

